Janssen Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceuticals Inc.
Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.
Celltrion CCO On The Big US Build-Up, Direct Sales Model
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.
Chinese Biotech Financing Rebounds But Mega Deals Missing
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.